Published in J Clin Invest on March 01, 1978
Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci U S A (1981) 3.03
Modulating influence of chemotactic factor-induced cell adhesiveness on granulocyte function. J Clin Invest (1979) 2.30
Human alveolar macrophage-derived chemotactic factor for neutrophils. Stimuli and partial characterization. J Clin Invest (1980) 2.04
The human eosinophil: roles in host defense and tissue injury. Am J Pathol (1980) 1.07
Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology (2004) 1.01
Local responses in primary and secondary human lung cancers. II. Clinical correlations. Br J Cancer (1979) 0.91
Inhibition of neutrophil chemotaxis in association with experimental angioedema in patients with cold urticaria: a model of chemotactic deactivation in vivo. Clin Exp Immunol (1979) 0.89
A novel eosinophil chemotactic factor derived from a histiocytic lymphoma of the central nervous system. Clin Exp Immunol (1980) 0.88
Presence of factors chemotactic for granulocytes in hypereosinophilic syndrome sera: relation with alterations in eosinophil migration. Clin Exp Immunol (1986) 0.85
Control of cellular influx in lung and its role in pulmonary toxicology. Environ Health Perspect (1984) 0.82
Tumour-associated eosinophilia in the bladder. J Clin Pathol (1984) 0.82
The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med (1962) 23.03
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
The hypereosinophilic syndromes. Ann Intern Med (1968) 3.60
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. J Clin Invest (1977) 3.10
Modification of the enzymatic isotopic assay of histamine and its application to measurement of histamine in tissues, serum and urine. Clin Chim Acta (1972) 2.92
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A (1975) 2.56
Gonadotropin-producing anaplastic large-cell carcinomas of the lung. N Engl J Med (1966) 2.27
Tumor-associated eosinophilotactic factor. N Engl J Med (1974) 2.27
Clinical and laboratory studies of ectopic humoral syndromes. Recent Prog Horm Res (1969) 2.16
Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid. J Clin Invest (1974) 1.81
Pseudohyperparathyroidism. Medicine (Baltimore) (1966) 1.70
Chemotactic deactivation of human eosinophils by the eosinophil chemotactic factor of anaphylaxis (38527). Proc Soc Exp Biol Med (1975) 1.68
Ectopic ACTH production in carcinoma of the lung. J Clin Invest (1974) 1.65
Modulation of human neutrophil polymorphonuclear leucocyte migration by human plasma alpha-globulin inhibitors and synthetic esterase inhibitors. Immunology (1975) 1.52
Preformed eosinophil chemotactic factor of anaphylaxis (ECF-A). J Immunol (1974) 1.40
Plasma and cell-derived inhibitors of human neutrophil chemotaxis. Ann N Y Acad Sci (1975) 1.32
Renal sodium loss and bronchogenic carcinoma. Associated autonomic neuropathy. Arch Intern Med (1961) 1.26
Subunits of human chorionic gonadotropin: unbalanced synthesis and secretion by clonal cell strains derived from a bronchogenic carcinoma. Proc Natl Acad Sci U S A (1973) 1.19
Eosinophilia following radiation therapy. Oncology (1973) 0.86
Incidence of intestinal parasites in Vietnam veterans. Eosinophilia a guide to diagnosis. Am J Gastroenterol (1972) 0.79
Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med (1976) 17.77
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Infection in organ-transplant recipients. N Engl J Med (1998) 6.49
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
Establishment of clonal strains of rat pituitary tumor cells that secrete growth hormone. Endocrinology (1968) 4.12
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med (1971) 4.07
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med (1990) 4.06
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol (1981) 3.71
Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med (1981) 3.63
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis. J Clin Invest (1975) 3.24
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol (1983) 3.18
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. J Clin Invest (1977) 3.10
The complement system of man. I. N Engl J Med (1972) 3.09
Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J Exp Med (1967) 3.08
A pre-albumin activator of prekallikrein. J Immunol (1970) 2.95
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs). J Immunol (1980) 2.93
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Affinity labeling of a mouse myeloma protein which binds nitrophenyl ligands. Kinetics of labeling and isolation of a labeled peptide. Biochemistry (1970) 2.88
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol (1975) 2.73
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A (1975) 2.56
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed Proc (1972) 2.55
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem (1998) 2.49
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
Studies in familial (medullary) thyroid carcinoma. Recent Prog Horm Res (1972) 2.47
Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med (1975) 2.46
Infective endocarditis--1973. Prog Cardiovasc Dis (1974) 2.42
Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (1981) 2.41
Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate. J Exp Med (1971) 2.39
Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest (1980) 2.37
Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem (1981) 2.37
Evidence that the bone resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E 2 . A new model for the hypercalcemia of cancer. J Exp Med (1972) 2.36
The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis. J Immunol (1973) 2.34
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. N Engl J Med (1978) 2.33
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med (1972) 2.31
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 2.27
Tumor-associated eosinophilotactic factor. N Engl J Med (1974) 2.27
Slow reacting substance of anaphylaxis. Adv Immunol (1969) 2.23
Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation (1981) 2.22
Hepatic abscess: changes in clinical, bacteriologic and therapeutic aspects. Am J Med (1974) 2.21
Generation of unique mono-hydroxy-eicosatetraenoic acids from arachidonic acid by human neutrophils. J Exp Med (1979) 2.20
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Inactivation of slow reacting substance of anaphylaxins (SRS-A) by arylsulfatases. J Immunol (1974) 2.19
Properdin factor D. II. Activation to D by properdin. J Exp Med (1974) 2.19
Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology (1970) 2.17
Effects of intravenous administration of slow-reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2alpha on pulmonary mechanics in the guinea pig. J Clin Invest (1974) 2.16
Cyclic AMP, ATP, and reversed anaphylactic histamine release from rat mast cells. J Immunol (1974) 2.16
O3-induced change in bronchial reactivity to methacholine and airway inflammation in humans. J Appl Physiol (1985) (1986) 2.16
Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest (1988) 2.15
Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate. J Biol Chem (1982) 2.13
Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli. Infect Immun (1989) 2.12
Characteristics of the cofactor requirements for the superoxide-generating NADPH oxidase of human polymorphonuclear leukocytes. Biochemistry (1981) 2.11
Novel structural determinants of the human neutrophil chemotactic activity of leukotriene B. J Exp Med (1981) 2.09
Molecular and cellular mechanisms of leukocyte chemotaxis. Science (1981) 2.07
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med (1980) 2.07
Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci U S A (1984) 2.06
Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats. J Bone Miner Res (1999) 2.05
Thyrotropin-releasing hormone regulates the number of its own receptors in the GH3 strain of pituitary cells in culture. Biochemistry (1975) 2.04
Heterogeneity of human polymorphonuclear leukocyte receptors for leukotriene B4. Identification of a subset of high affinity receptors that transduce the chemotactic response. J Exp Med (1984) 2.03
Inositol tetrakis- and pentakisphosphates in GH4 cells. J Exp Biol (1985) 2.02
Chemotactic and chemokinetic stimulation of human eosinophil and neutrophil polymorphonuclear leukocytes by 12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT). J Immunol (1978) 2.02
Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J Immunol (1979) 2.01
Production of both prolactin and growth hormone by clonal strains of rat pituitary tumor cells. Differential effects of hydrocortisone and tissue extracts. J Cell Biol (1970) 2.00